Estradiol transdermal - Ortho-McNeil

Drug Profile

Estradiol transdermal - Ortho-McNeil

Alternative Names: E(2)III; E2III

Latest Information Update: 03 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cygnus; Wyeth
  • Developer Ortho-McNeil
  • Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Atrophic vaginitis; Menopausal syndrome; Vasomotor symptoms

Most Recent Events

  • 20 Aug 2013 Biomarkers information updated
  • 20 Sep 1999 Registered for Vasomotor symptoms in USA (Transdermal)
  • 31 Dec 1998 Preregistration for Menopausal syndrome in European Union (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top